Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Sun Pharma Advanced Research Company Ltd Performance

Today's Low
332.55
arrowIcon
Today's High
332.55
52 Wk Low
178.80
arrowIcon
52 Wk High
472.80


Open

332.55

Traded Value (Cr)

2.11 Cr

Prev. Close

350.05

VWAP

332.55

Volume

83,387

Face Value

1

Sun Pharma Advanced Research Company Ltd Financials

Sun Pharma Advanced Research Company Ltd Financials

Sun Pharma Advanced Research Company Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 65.67 % 65.67 % 65.67 % 65.67 %
Retail 16.11 % 16.09 % 15.90 % 16.13 %
Others 14.73 % 14.70 % 14.53 % 14.35 %
FII 3.23 % 3.30 % 3.67 % 3.64 %
Mutual Funds 0.25 % 0.24 % 0.23 % 0.21 %

Promoters

65.67%

Retail

16.11%

Others

14.73%

FII

3.23%

Mutual Funds

0.25%

Promoters

65.67%

Retail

16.09%

Others

14.70%

FII

3.30%

Mutual Funds

0.24%

Promoters

65.67%

Retail

15.90%

Others

14.53%

FII

3.67%

Mutual Funds

0.23%

Promoters

65.67%

Retail

16.13%

Others

14.35%

FII

3.64%

Mutual Funds

0.21%

Resistance and Support

₹373.93

PIVOT

resistance-arrow
Resistance
First Resistance₹386.867
Second Resistance₹396.933
Third Resistance₹409.867
support-arrow
Support
First Resistance₹363.867
Second Resistance₹350.933
Third Resistance₹340.867
RSI40.740
MACD20.042
ADX19.545
CCI-137.241

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day83,38763,338100.00
Week61,05863,109100.00
1 Month261,960247,390100.00
6 Months83,38783,387100.00

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems. The Company works on innovation and new product development for global markets. They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Ltd was incorporated on March 1, 2006 as an innovative and development company. They commenced operations on March 22, 2006. As per Scheme of Arrangement, all assets and liabilities of the Innovative Research & Development business including Novel Drug Delivery System (NDDS) division of Sun Pharmaceuticals Industries' Research & Development undertaking stands transferred and vested in the Company with effect from Appointed date on February 28, 2007. The demerger became effective on March 28, 2007. On Scheme being effective, the Company ceased to be subsidiary of Sun Pharmaceutical Industries Ltd., and the demerged Company. During the year 2009-10, the Department of Scientific and Industrial Research (DSIR), Government of India sanctioned a 15 year unsecured soft loan under their Drug and Pharmaceutical Research Programme for a project of the Company. During 2011, the Company announced USFDA approval for DOCEFREZ (docetaxel) for Injection'. During 2014, the Company announced Govt. of India approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN). On 1 December 2014, Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for Latanoprost BAK-free eyedrops. While the FDA did not seek any additional information for supporting clinical data, it sought additional information on certain labeling and other deficiencies for processing the NDA. On 4 March 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for ELEPSIA XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg). ELEPSIA XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. The product will be manufactured by Sun Pharmaceutical Industries Ltd at its Halol (Gujarat) facility in India. On 9 June 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) and Sun Pharmaceutical Industries Ltd. announced that SPARC has licensed out Xelpros (Latanoprost BAK-free eye drops) to a subsidiary of Sun Pharma for the US market. On 1 August 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the U.S. Food and Drug Administration (USFDA) has issued a Complete Response letter (CRL) to its New Drug Application (NDA) for Xelpros, Latanoprost BAK-free eyedrops. SPARC submitted a response to an earlier CRL it had received from the USFDA, wherein no additional preclinical or clinical data was required. While the USFDA has accepted the clarifications and changes to the labeling, SPARC has now received another CRL from the USFDA seeking minor changes to the proposed labeling. SPARC hopes to address these requirements soon. This product is proposed to be manufactured at Sun Pharmaceutical Industries Ltd (SPIL)'s Halol facility and the USFDA has indicated that a satisfactory resolution of the cGMP deficiencies at this facility is a prerequisite for the final approval of Xelpros. SPARC had recently out-licensed this product to a subsidiary of Sun Pharmaceutical Industries Ltd (SPIL). On 25 September 2015, Sun Pharma Advanced Research Company Ltd. announced that the U.S. Food and Drug Administration (USFDA) has issued a Complete Response letter (CRL) to its New Drug Application (NDA) for Elepsia XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg). SPARC had earlier received a final approval from USFDA in March 2015 for this product and was evaluating several marketing partners for commercialization. However SPARC has now received a CRL from the USFDA rescinding its earlier approval, citing that the compliance status of the manufacturing facility was not acceptable on the date of approval. Elepsia XR is proposed to be manufactured at Sun Pharmaceutical Industries Ltd (SPIL)'s Halol facility. SPIL is working with USFDA in resolving the cGMP deviations at the facility and has taken several corrective measures. On 31 December 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) informed the stock exchanges that the management expects a possible further delay in the projected royalty income for the company from XELPROS (Latanoprost Ophthalmic Emulsion) and Elepsia XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg). This follows a warning letter to Sun Pharmaceutical Industries Ltd (SPIL) from the USFDA for its facility located at Halol, Gujarat in India. XELPROS and Elepsia XR are proposed to be manufactured at (SPIL)'s Halol facility. The Board of Directors of Sun Pharma Advanced Research Company Ltd. (SPARC) at its meeting held on 5 March 2016 approved rights issue of equity shares in the ratio of 5 equity shares for every 116 equity shares held as on the record date. The rights issue has been priced at Rs 245 per share. The company will raise upto Rs 250 crore from the rights issue. On 18 July 2016, Sun Pharma Advanced Research Company Ltd. (SPARC) and Sun Pharmaceutical Industries Ltd. announced a licensing arrangement for SPARC's ELEPSIA XR (Levetiracetam Extended Release tablets). As per the agreement, SPARC will license ELEPSIA XR (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma for the US market. SPARC will receive an up-front payment of US$10 million from Sun Pharma. It is also eligible for certain additional milestone payments and defined royalties linked to any future sales of ELEPSIA XR. On 22 December 2016, Sun Pharma Advanced Research Company Ltd. (SPARC) informed the stock exchanges that the company has received a Complete Response Letter (CRL) from the USFDA for the New Drug Application (NDA) for Xelpros, Latanoprost BAK-free eyedrops. The CRL references the recent inspection of Sun Pharmaceutical Industries Ltd.'s Halol manufacturing site by USFDA and indicates that satisfactory resolution of the deficiencies identified during the inspection is required before the final approval of Xelpros. There are no requirements of any additional data from USFDA in the CRL. SPARC had out-licensed Xelpros to a subsidiary of Sun Pharmaceutical Industries Ltd. in June 2015. On 19 May 2017, Sun Pharma Advanced Research Company Ltd. (SPARC) informed the stock exchanges that the company has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg. On 14 September 2018, Sun Pharmaceutical Industries Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) announced U.S. Food and Drug Administration (USFDA) approval for the New Drug Application (NDA) of XELPROS (latanoprost ophthalmic emulsion) 0.005% for the reduction of elevated intraocular pressure (IOP, or pressure inside the eye) in patients with open-angle glaucoma or ocular hypertension. This approval is from Sun Pharma's Halol (Gujarat, India) facility. Sun Pharma in-licensed XELPROS from SPARC in June 2015 and this approval will trigger a milestone payment to SPARC. SPARC is also eligible for milestone payments and royalties on commercialization of XELPROS in the US. In FY 2019-20, Company executed its 1st in-licensing agreement with Bioprojet (France) obtaining exclusive global rights of SCD-044. It also established first commercial partnership with China Medical Systems Ltd., out-licensing commercial rights of five assets (XelprosTM, ElepsiaTM, TaclantisTM, PDP-716 and SDN-037). SPARC's vodobatinib was granted orphan drug designation for treatment of CML. During the year, SPARC also commenced the investigator initiated study of SCC-138 in Lewy Body Dementia. It completed Phase I study of SCD-044. During FY 2021-22, Company progressed on multiple collaborative projects and also acquired exclusive rights for antibody against a unique oncology target from Biomodifying Inc. It licensed the commercialization rights for PDP-716 and SDN-037 to Visiox Pharma, a specialty pharma company focused on ophthalmology. The commercialization of ElepsiaTM XR commenced in 2021. It licensed the global (excluding India and greater China) commercialization rights to Visiox Pharma. On January 06, 2023 the Company had allotted 4,91,92,121 equity shares against the conversion of equal number of warrants issued on preferential basis. Consequent to the said allotment, Shanghvi Finance Private Limited (SFPL) has ceased to be the Company's Holding Company effective from the said date as its percentage shareholding along with its subsidiaries in the Company reduced from 52.07% to 44.18%. During FY23, SPARC along with Visiox completed the NDA submission to the USFDA in August 2023. SezabyTM Commercialization was commenced by Sun Pharma in Jan 2023.

Managing Director

Founded

2006

NSE Symbol

SPARC

Sun Pharma Advanced Research Company Ltd Management

NameDesignation
T RajamannarDirector
Sudhir V ValiaDirector
Bhavna DoshiIndependent Director
Ferzaan EngineerIndependent Director
Robert SpiegelIndependent Director
Dilip S ShanghviChairman (Non-Executive)

Sun Pharma Advanced Research Company Ltd News

Sun Pharma Advanced Research Company Ltd Slides 5%
Sun Pharma Advanced Research Company Ltd has added 14.83% over last one month compared to 5.15% gain in S&P BSE Healthcare index and 2.83% rise in the SENSEX
Sun Pharma Advanced Research Company reports standalone net loss of Rs 99.65 crore in the December 2023 quarter
Sales decline 89.43% to Rs 13.86 crore
Sun Pharma Advanced Research Company schedules board meeting
On 5 February 2024
Sun Pharma Advanced Research Company reports standalone net loss of Rs 86.42 crore in the September 2023 quarter
Sales decline 32.85% to Rs 21.18 crore
Sun Pharma Advanced Research Company enters into license agreement for SCD-153
With Johns Hopkins University (JHU) and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) (Licensors)
Sun Pharma Advanced Research Company to conduct board meeting
On 6 November 2023
Sun Pharma Advanced completes patient enrollment in PROSEEK study
For evaluation of Vodobatinib in treatment of patients with early Parkinson's disease
Volumes soar at Sun Pharma Advanced Research Company Ltd counter
Sun Pharma Advanced Research Company Ltd clocked volume of 55.05 lakh shares by 14:14 IST on NSE, a 28.08 times surge over two-week average daily volume of 1.96 lakh shares
Volumes jump at Sun Pharma Advanced Research Company Ltd counter
Sun Pharma Advanced Research Company Ltd witnessed volume of 1.28 lakh shares by 10:47 IST on BSE, a 6.96 times surge over two-week average daily volume of 18386 shares
Sun Pharma Advanced Research Company incorporates WOS in Delaware

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,65,370 Cr
₹ 1,522.80
(0.42 %)
88.68
CIPLA₹ 1,08,655 Cr
₹ 1,345.75
(-0.12 %)
33.03
DRREDDY₹ 99,137 Cr
₹ 5,942.85
(-0.24 %)
24.91
DIVISLAB₹ 97,472 Cr
₹ 3,671.70
(-1.00 %)
71.41
MANKIND₹ 93,635 Cr
₹ 2,337.45
(-2.43 %)
56.69

Sun Pharma Advanced Research Company Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Sun Pharma Advanced Research Company Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Sun Pharma Advanced Research Company Ltd's share price is ₹332.55 as of April 19, 2024

The 52-week high/low price of a Sun Pharma Advanced Research Company Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Sun Pharma Advanced Research Company Ltd's 52-week high and low as of April 19, 2024 are ₹332.55 and ₹332.55 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Sun Pharma Advanced Research Company Ltd stands at 65.67%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 3.30% to 3.23%.